B-ALL Clinical Trials

11 recruiting

Frequently Asked Questions

Common questions about B-ALL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Not Applicable

A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...

Acute Lymphoblastic LeukemiaB-ALL
National Cancer Institute (NCI)60 enrolled8 locationsNCT05621291
Recruiting
Phase 1Phase 2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Acute Lymphoblastic LeukemiaLymphoma, Non-HodgkinB-cell Lymphoma+8 more
National Cancer Institute (NCI)126 enrolled1 locationNCT05442515
Recruiting
Phase 2

Orphan Indications for CD19 Redirected Autologous T Cells

Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Stephan Grupp MD PhD133 enrolled1 locationNCT04276870
Recruiting
Phase 1Phase 2

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca83 enrolled26 locationsNCT07109219
Recruiting
Phase 3

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

B-ALLMRD-positiveAllogenetic Hematopoietic Stem Cell Transplantation
Peking University People's Hospital70 enrolled1 locationNCT07441291
Recruiting

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

B-cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-cell Acute Lymphoblastic Leukemia (B-ALL)+5 more
Arkansas Children's Hospital Research Institute300 enrolled2 locationsNCT07422337
Recruiting
Early Phase 1

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Diffuse Large B Cell LymphomaB-ALLDLBCL Unclassifiable+7 more
Memorial Sloan Kettering Cancer Center12 enrolled7 locationsNCT04512716
Recruiting
Phase 1Phase 2

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca163 enrolled79 locationsNCT06137118
Recruiting
Early Phase 1

JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

B-cell Acute Lymphoblastic Leukemia (B-ALL)
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China20 enrolled1 locationNCT06514768
Recruiting
Phase 1Phase 2

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

B-cell Acute Lymphoblastic Leukemia (B-ALL)B Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD89 enrolled1 locationNCT05480449
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)Autoimmune Hemolytic Anemia, AIHA+1 more
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Phase 1

KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

B-ALL
Zhejiang University30 enrolled1 locationNCT07246707
Recruiting
Phase 2

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

B-ALL
Hebei Senlang Biotechnology Inc., Ltd.59 enrolled1 locationNCT07244406
Recruiting

CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions

B-cell Acute Lymphoblastic Leukemia (B-ALL)
St. Jude Children's Research Hospital80 enrolled1 locationNCT07048535
Recruiting
Phase 1

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

B-ALLAML/MDST-ALL+1 more
St. Jude Children's Research Hospital108 enrolled2 locationsNCT04318678
Recruiting
Phase 2Phase 3

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

Childhood Leukemia, Acute LymphoblasticB-cell Acute Lymphoblastic Leukemia (B-ALL)Acute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China3,000 enrolled27 locationsNCT06882057
Recruiting
Not Applicable

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

B-ALLB-NHL
Tongji Hospital20 enrolled1 locationNCT06689917
Recruiting
Not Applicable

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

B-ALLB-cell Acute Lymphoblastic Leukemia (B-ALL)Philadelphia Chromosome Negative
University of Chicago20 enrolled1 locationNCT06785324
Recruiting
Phase 1Phase 2

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

AML (Acute Myelogenous Leukemia)B-ALLMyeloma, Multiple+3 more
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710
Recruiting
Phase 2Phase 3

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Childhood Leukemia, Acute LymphoblasticB-cell Acute Lymphoblastic Leukemia (B-ALL)Acute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China1,800 enrolled26 locationsNCT06764238